"Imidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
| Descriptor ID |
D007093
|
| MeSH Number(s) |
D03.383.129.308
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Imidazoles".
Below are MeSH descriptors whose meaning is more specific than "Imidazoles".
This graph shows the total number of publications written about "Imidazoles" by people in this website by year, and whether "Imidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 2 | 3 |
| 2005 | 2 | 5 | 7 |
| 2006 | 3 | 3 | 6 |
| 2007 | 2 | 1 | 3 |
| 2008 | 3 | 4 | 7 |
| 2009 | 4 | 2 | 6 |
| 2010 | 3 | 2 | 5 |
| 2011 | 3 | 0 | 3 |
| 2012 | 7 | 3 | 10 |
| 2013 | 2 | 4 | 6 |
| 2014 | 4 | 2 | 6 |
| 2015 | 10 | 7 | 17 |
| 2016 | 8 | 3 | 11 |
| 2017 | 4 | 3 | 7 |
| 2018 | 5 | 4 | 9 |
| 2019 | 3 | 5 | 8 |
| 2020 | 3 | 4 | 7 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imidazoles" by people in Profiles.
-
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer. 2024 Oct 30; 12(10).
-
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. Br J Cancer. 2024 Dec; 131(11):1846-1857.
-
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol. 2024 Nov; 11(11):e839-e849.
-
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. Am J Hematol. 2024 Nov; 99(11):2229-2232.
-
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol. 2024 Dec 20; 42(36):4246-4251.
-
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 Nov 07; 391(18):1709-1720.
-
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2024 06 04; 331(21):1814-1823.
-
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer. ESMO Open. 2024 Jun; 9(6):103465.
-
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer. 2024 Oct 01; 130(19):3344-3352.
-
Ponatinib-review of historical development, current status, and future research. Am J Hematol. 2024 08; 99(8):1576-1585.